Renaissance Technologies LLC Purchases 169,100 Shares of Halozyme Therapeutics, Inc. $HALO

Renaissance Technologies LLC lifted its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 30.1% in the first quarter, HoldingsChannel.com reports. The firm owned 731,811 shares of the biopharmaceutical company’s stock after acquiring an additional 169,100 shares during the period. Renaissance Technologies LLC’s holdings in Halozyme Therapeutics were worth $47,297,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently bought and sold shares of the company. Inceptionr LLC bought a new position in shares of Halozyme Therapeutics during the 1st quarter worth about $771,000. Mizuho Markets Americas LLC boosted its position in shares of Halozyme Therapeutics by 4.3% during the 1st quarter. Mizuho Markets Americas LLC now owns 1,323,544 shares of the biopharmaceutical company’s stock valued at $85,541,000 after acquiring an additional 54,871 shares in the last quarter. Gibbs Wealth Management increased its stake in Halozyme Therapeutics by 191.8% in the first quarter. Gibbs Wealth Management now owns 9,049 shares of the biopharmaceutical company’s stock valued at $585,000 after acquiring an additional 5,948 shares during the period. First Citizens Bank & Trust Co. increased its stake in Halozyme Therapeutics by 2.0% in the first quarter. First Citizens Bank & Trust Co. now owns 9,088 shares of the biopharmaceutical company’s stock valued at $587,000 after acquiring an additional 175 shares during the period. Finally, First Trust Advisors LP raised its position in Halozyme Therapeutics by 46.5% in the first quarter. First Trust Advisors LP now owns 1,482,340 shares of the biopharmaceutical company’s stock worth $95,804,000 after purchasing an additional 470,558 shares in the last quarter. Institutional investors and hedge funds own 97.79% of the company’s stock.

Insider Transactions at Halozyme Therapeutics

In other news, Director Mahesh Krishnan sold 7,304 shares of the firm’s stock in a transaction on Monday, June 29th. The stock was sold at an average price of $75.00, for a total value of $547,800.00. Following the completion of the sale, the director directly owned 14,462 shares in the company, valued at approximately $1,084,650. This trade represents a 33.56% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bernadette Connaughton sold 1,625 shares of Halozyme Therapeutics stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $76.71, for a total value of $124,653.75. Following the completion of the transaction, the director directly owned 42,044 shares of the company’s stock, valued at $3,225,195.24. This represents a 3.72% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 74,102 shares of company stock worth $5,205,798. Insiders own 2.50% of the company’s stock.

Halozyme Therapeutics Price Performance

Shares of Halozyme Therapeutics stock opened at $81.48 on Tuesday. The stock has a market capitalization of $9.66 billion, a price-to-earnings ratio of 29.31, a P/E/G ratio of 0.34 and a beta of 0.84. The firm’s 50-day moving average price is $73.36 and its two-hundred day moving average price is $70.63. The company has a current ratio of 2.76, a quick ratio of 2.33 and a debt-to-equity ratio of 8.81. Halozyme Therapeutics, Inc. has a 1-year low of $57.67 and a 1-year high of $83.50.

Halozyme Therapeutics (NASDAQ:HALO) last announced its earnings results on Monday, May 11th. The biopharmaceutical company reported $1.60 EPS for the quarter, topping the consensus estimate of $1.54 by $0.06. Halozyme Therapeutics had a return on equity of 187.91% and a net margin of 23.13%.The business had revenue of $376.71 million for the quarter, compared to the consensus estimate of $358.60 million. During the same period in the previous year, the business earned $1.11 EPS. Halozyme Therapeutics’s revenue was up 42.2% compared to the same quarter last year. Halozyme Therapeutics has set its FY 2026 guidance at 7.750-8.250 EPS. On average, equities analysts predict that Halozyme Therapeutics, Inc. will post 7.54 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

HALO has been the subject of a number of analyst reports. Morgan Stanley cut their price target on shares of Halozyme Therapeutics from $96.00 to $93.00 and set an “overweight” rating for the company in a research note on Tuesday, May 12th. UBS Group reiterated a “buy” rating and issued a $90.00 price objective on shares of Halozyme Therapeutics in a research note on Wednesday, June 3rd. HC Wainwright reissued a “buy” rating and issued a $95.00 target price on shares of Halozyme Therapeutics in a report on Tuesday, July 21st. Weiss Ratings upgraded Halozyme Therapeutics from a “hold (c)” rating to a “buy (b-)” rating in a research report on Tuesday, May 12th. Finally, Wall Street Zen raised Halozyme Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, May 16th. Eight investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $81.60.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.